Affimed N.V.
Stock Exchange NASDAQ Stock Market
EPS
$0.18
Market Cap
$181.67 M
Shares Outstanding
62.43 M
Public Float
47.61 M

Profile

Address
Technologiepark
Heidelberg Baden Wuerttemberg 69120
Germany
Employees -
Website http://www.affimed.com
Updated 07/08/2019
Affimed NV is a clinical stage biopharmaceutical company, which engages in discovering and developing highly targeted cancer immunotherapies. The company has three proprietary platform technologies which includes: NK-cell TandAbs, T-cell TandAbs and Trispecific Abs. The company was founded in 2000 and is headquartered in Heidelberg, Germany.

Financials

View All
Created with Highcharts 5.0.14Affimed N.V.Net Income. Fiscal year is January-December. All values USD Thousands.34 64934 64934334322 44322 44335 63735 63734 08934 08922 97822 978201320142015201620172018010k20k30k40k
Created with Highcharts 5.0.14Affimed N.V.Sales/Revenue. Fiscal year is January-December. All values USD Thousands.6 7536 7534 4864 4868 3858 3856 9846 9842 2672 26728 00128 00120132014201520162017201805k10k15k20k25k30k

Mathieu Simon
Member-Supervisory Board
Ulrich M. Grau
Member-Supervisory Board